Neutralization of a chimeric human immunodeficiency virus (HIV) type 1, containing the V3 loop of the MN isolate substituted within the HXB2 envelope, was enhanced up to 20-fold compared with the HXB2 or MN parental isolates by human HIV-positive sera. MN V3 loop-specific monoclonal antibodies were better able to recognize the chimeric virus compared with MN, staining a greater percentage of infected cells and exhibiting slight increases in relative affinity with a concomitant increase in neutralization titer. Competition analysis revealed that enhanced neutralization by human HIV-positive sera of the chimera was attributable in some cases to better reactivity with the linear V3 loop epitope but in others to conformational loop epitopes or previously cryptic or poorly recognized epitopes outside the loop region. Mice primed with a vaccinia virus-chimeric envelope recombinant and boosted with gpl60 developed a spectrum of antibodies different from that of mice similarly immunized with HXB2 or MN recombinants or that of naturally infected humans. The chimeric envelope elicited antibodies with enhanced binding to the native MN V3 loop; however, the sites seen by the BALB/c mice were not neutralizing epitopes. Nevertheless, similar to the observations made with use of human sera, the chimeric virus was more readily neutralized by all of the immune mouse sera, an effect apparently mediated by non-V3 loop epitopes. These studies illustrate that not only the V3 loop sequence and conformation but also its context within the viral envelope influence neutralization.
The V3 loop of human immunodeficiency virus type 1 (HIV-1) consists of approximately 33 amino acids residing between two cysteine residues in the third variable domain of the viral envelope protein. It is a principal type-specific neutralizing determinant of the virus (15, 25, 30, 37) and also elicits virus-specific cytotoxic T lymphocytes and T-helper cell immune responses (2) . The loop influences viral tropism (19, 39, 45) , perhaps in part by providing a target for digestion by cellular proteases as part of the infection process (16, 24, 42 ). An attractive hypothesis suggests that cleavage of the V3 loop mediates fusion of virus with target cells following CD4 binding (5) . For these reasons, it was of interest to be able to study V3 loops with divergent sequences within a known, well-characterized envelope background. A V3 loop cassette was constructed by using the infectious molecular clone HXB2 (11) as a framework into which a V3 loop corresponding to the sequence of any isolate could be substituted (7) . We have used one such chimeric virus, containing the V3 loop of HIV-1MN, to study the effect of the V3 loop on neutralization by sera of naturally infected HIV-seropositive humans. Our approach was to compare the ability of these sera to neutralize the chimera with their ability to neutralize the two parental viruses. The contribution of the linear V3 loop itself compared with regions outside the loop or conformationally dependent V3 loop epitopes was evaluated by competition experiments using V3 loop peptides. Our results show that the exchange of one V3 loop for another has profound effects on the overall conformation of the gpl60 framework, modulating V3 loop epitopes and perhaps uncovering cryptic sites outside the V3 loop or altering poorly recognized ones. As a result, the resultant molecule exhibits greater immunologic reactivity with immune sera than does either unmodified parental envelope. Such chimeric immunogens may find applicability in HIV vaccine design.
MATERIALS AND METHODS
Viruses. HIV-1 isolates used in neutralization assays included the infectious molecular clone of HIV-lI,,B designated HXB2 (11) , HIV-1MN (14, 40) , and the HXB2/MNLoop construct composed of HXB2 with a chimeric envelope containing the V3 loop of MN substituted for the V3 loop of HXB2. This chimeric virus was constructed by using a V3 loop cassette previously described (7) . The cassette, containing the 2.7-kbp SalI-BamHI env fragment of HXB2, contains MluI and HpaI restriction sites at the borders of the V3 loop, which are separated by a short stretch of DNA containing a PstI site (Fig.  la) . The V3 loop of MN was inserted by annealing the four primers illustrated in Fig. lb and ligating RESULTS Enhanced neutralization of chimeric virus by human sera. The ability of 11 HIV antibody-positive sera from the United States and Europe and 10 from Zaire to inhibit the infectivity of standard HXB2 and MN isolates and the HXB2/MNLoop chimera was assessed in a cell-free neutralization assay. As shown in Table 1 , the sera were in general able to neutralize all three viruses, although the U.S./European sera tended to neutralize MN better than HXB2, while the opposite was true for the Zairian sera. In both cases, enhanced neutralization of the HXB2/MNLoop chimera was observed. Mean neutralizing titers of U.S./European sera were 12-fold greater against the chimera compared with HXB2 and 3-fold greater compared with MN. The enhanced neutralization of the chimeric virus compared with MN by Zairian sera was even more pronounced, with a 20-fold difference observed. These Zairian sera neutralized the chimera with fivefold-higher titers compared with HXB2.
Characterization of parental and chimeric viruses. To determine if the enhanced neutralization of the chimeric virus was due to altered growth characteristics or viral properties leading to greater ease of neutralization, several virological characteristics of the parental and chimeric viruses were compared and are summarized in Table 2 . Viral protein expression, including reverse transcriptase activity and p24 and gpl20 levels, in supernatant media from infected H9 cultures was comparable for the three viruses. Furthermore, the percentages of gpl20 in the viral pellet fraction compared with that found free in the culture supernatant were similar for the parental and chimeric viruses, indicating that one virus did not shed its envelope more rapidly than another. With regard to infectivity, the infectious titers of the viruses were all in the same range. In addition, the kinetics of infection of the three viruses were similar when cell-free supernatant medium was used to infect H9 cells (not shown). Thus, the enhanced neutralization of the chimeric virus appeared to be based on immunologic recognition rather than altered replicability or infectivity. (40) sible for the enhanced neutralization of the chimeric virus by serum C. Immunogenicity of the chimeric envelope in vivo. The enhanced neutralization of the HXB2/MNLoop chimera by human sera seropositive for HIV-1 suggested that the envelope of this virus might provide an immunogen capable of eliciting broadly neutralizing antibodies of high titer and/or affinity. This hypothesis was tested by immunizing mice in a primeboost protocol, chosen because purified envelope protein of the chimeric virus was not available. The mice were primed with two immunizations of a vaccinia virus recombinant containing either the HXB2, MN, or HXB2/MNLoop gpl20. All constructs contained all or part of the IIIB/Lai gp4l as outlined in Materials and Methods. Our previous results have suggested that a protein subunit booster is necessary for eliciting good neutralizing antibody activity following priming with vaccinia virus-HIV-1 recombinants (1). Therefore, a mixed booster inoculation consisting of native IIIB and MN/Lai envelopes was given to all mice. The results of this experiment are shown in Tables 4 to 6. Contrary to our expectation, immunization with chimeric envelope did not result in enhanced neutralization of any of the three viruses (Table 4 ). In fact, mice immunized with either the MN/Lai or IIIB construct exhibited greater ability to neutralize the three isolates than did mice immunized with the chimera, both in number of neutralizing sera per group and in overall titer. Sera of mice immunized with the HXB2/MNLoop chimera exhibited poor reactivity to the linear MN V3 loop, as shown by their failure to neutralize the MN virus and their minimal binding to the linear MN V3 loop peptide (Table 5) . Thus, they were precluded from showing enhanced neutralization due to a linear MN V3 loop epitope.
Recognition of HXB2/MNLoop
Comparisons of the three mouse groups overall revealed that regardless of immunogen, the chimeric virus was more readily neutralized than either parental strain, with regard to both number of sera able to neutralize (12 of 15) and overall mean titer (100 for HXB2/MNLoop, 40 for MN, and 50 for HXB2). This ready neutralization of the chimeric virus appears to be mediated primarily by epitopes outside the V3 loop or by conformationally dependent V3 loop epitopes, a conclusion supported by results of the V3 binding studies ( Table 5 ). The linear MN V3 loop was poorly recognized by sera of any of the (15, 25, 30, 37) , other neutralizing epitopes exist across the viral envelope, including regions in the C2 (17) and V2 (12) domains of gpl20 and in gp4l (4) . In addition to these linear epitopes, conformational neutralization sites suggested by earlier studies (26, 34, 41) have been substantiated by studies of animal derived and human MAb (6, 18, 21, 33, 43) . Recent work, in fact, suggests that antibodies which recognize conformational epitopes represent a much larger proportion of the neutralizing antibody repertoire in infected humans than those which bind to linear ones (28) . Clearly, a spectrum of neutralizing epitopes subject to modulation by conformational changes exists, as has been readily demonstrated by studies of immune-selected neutralization-resistant HIV escape mutants (23, 29, 44, 47 Attempts to demonstrate increased immunogenicity of the chimeric virus in mice were not completely successful. Although the chimeric virus primed for enhanced recognition of the native MN V3 loop, the particular V3 loop epitopes recognized by the BALB/c mice were not neutralizing. Nevertheless, the experiments confirmed our observations obtained by using human sera of enhanced neutralizability of the chimera. In mice, this enhancement appeared to be primarily due to alteration of non-V3 loop epitopes. Use of the chimeric envelope as immunogen should be further evaluated in a nonhuman primate model, in which functional immune responses would be expected to more closely represent those of humans. We believe that the V3 loop chimera approach has great utility for elucidation of multiple envelope-neutralizing determinants as well as a potential utility for vaccine development. 
